Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Amphotericin B Liposome vs AmBisome in Healthy Subjects
NCT05913921Phase 1Completed
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Jun 2023
- Primary completion
- Sep 2023
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liposomal amphotericin b in fungal infection, sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to the last measurable concentration and 1 more. Started Jun 2023; status: completed.
02
Drugs
liposomal amphotericin b
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT05913921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913921.